Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.48 – $3.15
Volume8,968
Market cap$57M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NORD.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NORD.
Recent news
Company coverage with links to the original publishers.
Nordicus Partners announced positive preclinical results for its subsidiary Orocidin's QR-01 treatment for aggressive periodontitis, demonstrating efficacy in both beagle and rat studies with reduced bone loss confirmed by micro-CT imaging. Phase IIa clinical trials are planned for H1 2027 at the University of Copenhagen. Bio-Convert received a toxicity waiver for QR-02 (oral leukoplakia treatment) with GMP manufacturing on track for December 2026, while NoviThera established biological proof of concept for QR-04 psoriasis treatment. The company's Nasdaq uplisting application remains under active review.
Orocidin, a subsidiary of Nordicus Partners Corporation, has announced a strategic partnership with Syngene International to advance Orocidin's QR-01 peptide program. The partnership will leverage Syngene's expertise in GMP peptide development and manufacturing to support Orocidin's efforts to bring new drugs to market faster and more reliably.
Nordicus Partners Corporation announced that its subsidiary, Orocidin A/S, will initiate a toxicity program for its proprietary product Orocidin (QR-01), which aims to treat periodontitis by reducing inflammation, eradicating bacterial infections, and promoting bone regeneration.
Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a Consultancy Agreement with BIO-CONVERT in Denmark.
Beverly Hills, California., June 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, and its 95% owned subsidiary, Orocidin A/S (“Orocidin”), announced today new insights into the treatment of periodontitis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Apr 24, 2020
$1.80
Apr 23, 2020
special
Stock splits
Historical share-structure events and their execution dates.